.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The ROSE trial tested whether early continuous neuromuscular blockade with cisatracurium improves outcomes in patients with moderate-to-severe ARDS who are managed with mechanical ventilation. Patients were randomised to a 48-hour infusion with deep sedation or to usual care without routine paralysis and with lighter sedation targets. The study found no significant difference in 90-day mortality or days free of mechanical ventilation between the two groups. These results contrasted with the earlier ACURASYS trial and were influential in redefining when paralysis should be considered. A key difference was that the usual-care group in ROSE received contemporary lung-protective ventilation and high-quality supportive care, including lighter sedation. The findings suggest that routine paralysis for all patients with moderate-to-severe ARDS is not necessary. Instead, neuromuscular blockade can be reserved for selected situations such as severe ventilator dyssynchrony, inability to maintain lung-protective targets despite appropriate sedation, or other specific clinical indications. The trial also reinforces the importance of minimising deep sedation whenever possible because lighter sedation can support mobilisation, communication and neurologic assessment. For clinicians, ROSE is a reminder that a treatment can remain useful as a rescue tool even when it is not beneficial as a universal protocol.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The ROSE trial tested whether early continuous neuromuscular blockade with cisatracurium improves outcomes in patients with moderate-to-severe ARDS who are managed with mechanical ventilation. Patients were randomised to a 48-hour infusion with deep sedation or to usual care without routine paralysis and with lighter sedation targets. The study found no significant difference in 90-day mortality or days free of mechanical ventilation between the two groups. These results contrasted with the earlier ACURASYS trial and were influential in redefining when paralysis should be considered. A key difference was that the usual-care group in ROSE received contemporary lung-protective ventilation and high-quality supportive care, including lighter sedation. The findings suggest that routine paralysis for all patients with moderate-to-severe ARDS is not necessary. Instead, neuromuscular blockade can be reserved for selected situations such as severe ventilator dyssynchrony, inability to maintain lung-protective targets despite appropriate sedation, or other specific clinical indications. The trial also reinforces the importance of minimising deep sedation whenever possible because lighter sedation can support mobilisation, communication and neurologic assessment. For clinicians, ROSE is a reminder that a treatment can remain useful as a rescue tool even when it is not beneficial as a universal protocol.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
